TAC1: A Potential Drug Target and Biomarker for Tachykinin precursor 1

Target Name: TAC1

NCBI ID: G6863

TAC1

TAC1: A Potential Drug Target and Biomarker for Tachykinin precursor 1

Abstract:

Tachykininin precursor 1 (TAC1) is a protein that has been identified as a potential drug target and biomarker for various diseases, including heart disease, cancer, and neurodegenerative disorders. This article reviews the current understanding of TAC1, its potential drug target status, and its potential as a biomarker for disease.

Introduction:

Tachykininin precursor 1 (TAC1) is a protein that is expressed in various tissues and cells, including cardiac muscle, heart failure cells, and cancer cells. It is a key player in the regulation of pain perception and neurotransmitter release, and has been implicated in various diseases, including heart disease, cancer, and neurodegenerative disorders.

Potential Drug Target Status:

TAC1 has been identified as a potential drug target due to its involvement in pain perception and neurotransmitter release. Several studies have shown that TAC1 interacts with various neurotransmitters, including nitric oxide, serotonin, and dopamine. Additionally, TAC1 has been shown to regulate the release of various neurotransmitters, including GABA and glutamate. These findings suggest that TAC1 may be a promising drug target for the treatment of pain, neurodegenerative disorders, and other conditions that involve neurotransmitter regulation.

Potential Biomarker Status:

TAC1 has also been identified as a potential biomarker for various diseases. Its expression has been shown to be elevated in various disease states, including heart failure, cancer, and neurodegenerative disorders. Additionally, TAC1 has been shown to be involved in the regulation of pain perception and neurotransmitter release, which may be useful as a biomarker for pain management.

Current Research:

Current research is focused on the characterization of TAC1 as a drug target and biomarker. Several studies have shown that TAC1 can be targeted with small molecules, including inhibitors of nitric oxide synthesis and GABA receptors. Additionally, TAC1 has been shown to interact with various biomarkers for disease, including the efficacy of a small molecule inhibitor for TAC1 in animal models of neurodegenerative disorders.

Conclusion:

Tac1 is a protein that has been identified as a potential drug target and biomarker for various diseases. Its interaction with neurotransmitters and its regulation of pain perception and neurotransmitter release make it a promising target for the treatment of pain, neurodegenerative disorders, and other conditions that involve neurotransmitter regulation. Further research is needed to fully understand the potential of TAC1 as a drug target and biomarker.

Protein Name: Tachykinin Precursor 1

Functions: Tachykinins are active peptides which excite neurons, evoke behavioral responses, are potent vasodilators and secretagogues, and contract (directly or indirectly) many smooth muscles

The "TAC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets